- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05447390
Evaluation of the Strength of Handgrip in Patients With Pulmonary Artery Hypertension
Our study aims to investigate the changes in muscle strength and muscle mass in PAH patients compared to healthy individuals and determine its effects on prognosis.
Further categorization of PAH patients based on their NYHA class will help determine if their handgrip strength decreases while progressing from NYHA class 1 to 4. This in turn allows us to examine if the handgrip test can be considered as an alternative to a 6-minute walking test (6MWT).
The Jamar Hydraulic Hand Dynamometer device in our hospital is used for measuring the handgrip strength test.
The data of the included subjects in this study are obtained and recorded from the existing files. Also, the handgrip strength test data will be recorded after the investigation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey, 06560
- Gazi University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Pulmonary Hypertension Group:
- Diagnosed with Pulmonary Hypertension and attending the clinic for follow-ups.
- Older than 5 years.
Healthy Control Group
- Individuals without any known diseases, structural Cardiac anomalies, familial history of heart diseases and sudden death.
- Older than 5 years.
Exclusion Criteria:
Volunteers' Rejection Criteria:
- Younger than 5 years.
Mental state disorders which will cause inaccuracies in the study's
i. Volunteers' Dismissal Criteria:
- Inadaptation to the study's steps.
- If subjects become reluctant to continue with the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Healthy Control
|
The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
|
|
Active Comparator: Pulmonary Hypertension
|
The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the strength of handgrip in patients with pulmonary artery hypertension
Time Frame: Baseline
|
Investigate and evaluate of the strength of handgrip in patients with pulmonary artery hypertension with hand dynamometer compared to healthy individuals.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the strength of handgrip in patients with pulmonary artery hypertension
Time Frame: Baseline
|
Further categorization of PAH patients based on their NYHA class will help determine if their handgrip strength decreases while progressing from NYHA class 1 to 4. This in turn allows us to examine if the handgrip test can be considered as an alternative to a 6-minute walking test (6MWT).
|
Baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, Budts W, D'Alto M, Gatzoulis MA, Hasan BS, Kozlik-Feldmann R, Kumar RK, Lammers AE, Latus H, Michel-Behnke I, Miera O, Morrell NW, Pieles G, Quandt D, Sallmon H, Schranz D, Tran-Lundmark K, Tulloh RMR, Warnecke G, Wahlander H, Weber SC, Zartner P. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019 Sep;38(9):879-901. doi: 10.1016/j.healun.2019.06.022. Epub 2019 Jun 21.
- Kula S, Pektas A. A review of pediatric pulmonary hypertension with new guidelines. Turk J Med Sci. 2017 Apr 18;47(2):375-380. doi: 10.3906/sag-1605-172.
- Di Rienzo A, Felicetti L, Novelletto A, Forteleoni G, Colombo B. Frequency and types of deletional alpha+-thalassemia in northern Sardinia. Hum Genet. 1985;71(2):147-9. doi: 10.1007/BF00283371.
- Neidenbach RC, Oberhoffer R, Pieper L, Freilinger S, Ewert P, Kaemmerer H, Nagdyman N, Hager A, Muller J. The value of hand grip strength (HGS) as a diagnostic and prognostic biomarker in congenital heart disease. Cardiovasc Diagn Ther. 2019 Oct;9(Suppl 2):S187-S197. doi: 10.21037/cdt.2019.09.16.
- Mathiowetz V, Wiemer DM, Federman SM. Grip and pinch strength: norms for 6- to 19-year-olds. Am J Occup Ther. 1986 Oct;40(10):705-11. doi: 10.5014/ajot.40.10.705.
- Hager-Ross C, Rosblad B. Norms for grip strength in children aged 4-16 years. Acta Paediatr. 2002;91(6):617-25. doi: 10.1080/080352502760068990.
- Ploegmakers JJ, Hepping AM, Geertzen JH, Bulstra SK, Stevens M. Grip strength is strongly associated with height, weight and gender in childhood: a cross sectional study of 2241 children and adolescents providing reference values. J Physiother. 2013 Dec;59(4):255-61. doi: 10.1016/S1836-9553(13)70202-9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-397
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Poitiers University HospitalNot yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Guangdong Provincial People's HospitalRecruitingIdiopathic Pulmonary HypertensionChina
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States
Clinical Trials on Handgrip strength test
-
CHU de ReimsCompletedChemotherapy | Sarcopenia | Muscle Strength | Digestive Cancer | Handgrip Strength Test
-
Hannah SchaeferRecruitingKidney Disease | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Radiation NephropathyGermany
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Cliniques universitaires Saint-Luc- Université...CompletedFrailty | Perioperative/Postoperative Complications | Olfactory DisorderBelgium
-
Thammasat UniversityCompletedChronic Obstructive Pulmonary DiseaseThailand
-
University of LiegeUnknownQuality of Life | Critical Illness | Muscle Strength | Grip Strength | Quadriceps StrengthBelgium
-
Centre Hospitalier Régional d'OrléansCompletedEffect of Vibratory Tendon Stimulation on Muscle Fatigue in the Acute Post-stroke Phase (VIBRAMAIN1)Stroke | Fatigue | Stroke, AcuteFrance
-
University of SouthamptonUniversity Hospital Southampton NHS Foundation TrustUnknownInflammatory Bowel Disease | Nutrition
-
Shanxi Provincial People's HospitalThe First Affiliated Hospital of Henan University of Science and TechnologyCompletedHandgrip Strength | Transjugular Intrahepatic Portosystemic Shunts (TIPS)China
-
Riphah International UniversityCompletedSports Physical TherapyPakistan